Keiko Inakami, Noriko Fujita, Chikage Iguchi, Yukie Enomoto, Junya Minohata, Atsushi Sata, Yoshimasa Miyagawa, Tetsu Yanagisawa, Tomokazu Saitoh, Takashi Nomura, Yuka Sawai, Keiko Takahara, Tsutomu Kasugai, Eiichi Shiba
BACKGROUND: Pembrolizumab (PEM), an immune checkpoint inhibitor (ICI), is often used for triple-negative breast cancer, but can also be used to treat solid tumors that exhibit high microsatellite instability (MSI-High). However, patients with breast cancer rarely have MSI-High, the use of PEM in such cases in clinical practice is uncertain due to lack of sufficient supporting data. Here, we report the case of a premenopausal woman in who received PEM for MSI-High luminal-type breast cancer...
May 1, 2024: Journal of Medical Case Reports